Compare OLN & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLN | INSP |
|---|---|---|
| Founded | 1892 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 1994 | 2018 |
| Metric | OLN | INSP |
|---|---|---|
| Price | $14.88 | $68.85 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 18 |
| Target Price | $20.20 | ★ $65.00 |
| AVG Volume (30 Days) | ★ 3.7M | 863.2K |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,780,800,000.00 | $82,050,000.00 |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $4.99 | $3.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.68 | ★ 62.18 |
| 52 Week Low | $14.95 | $38.91 |
| 52 Week High | $30.46 | $147.03 |
| Indicator | OLN | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 52.26 |
| Support Level | $14.95 | $68.13 |
| Resistance Level | $24.81 | $75.31 |
| Average True Range (ATR) | 0.60 | 3.25 |
| MACD | -0.00 | -0.88 |
| Stochastic Oscillator | 1.56 | 31.75 |
Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.